CN104083689A - Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing nasopharyngeal carcinoma - Google Patents
Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing nasopharyngeal carcinoma Download PDFInfo
- Publication number
- CN104083689A CN104083689A CN201410173967.XA CN201410173967A CN104083689A CN 104083689 A CN104083689 A CN 104083689A CN 201410173967 A CN201410173967 A CN 201410173967A CN 104083689 A CN104083689 A CN 104083689A
- Authority
- CN
- China
- Prior art keywords
- hayata
- stahlianthus hainanensis
- stahlianthus
- volatile oil
- hainanensis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a new use of Stahlianthus involucratus (King) Craib, a Stahlianthus involucratus (King) Craib extract, a Stahlianthus involucratus (King) Craib fat-soluble extract and a Stahlianthus involucratus (King) Craib volatile oil composition, that is, a new use in the preparation of drugs for treating and/or preventing nasopharyngeal carcinoma.
Description
Technical field
The present invention relates to the new purposes of Stahlianthus hainanensis (Hayata) T. L. Wu, Stahlianthus hainanensis (Hayata) T. L. Wu extract, Stahlianthus hainanensis (Hayata) T. L. Wu liposoluble extract and Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, in preparation, treat and/or prevent the new purposes aspect medicine for nasopharyngeal.
Background technology
Nasopharyngeal carcinoma refers to the malignant tumor that betides cavum nasopharyngeum top and sidewall.Be one of China's malignant tumor occurred frequently, sickness rate is first of ear,nose & throat malignant tumor.Common symptoms is for being with blood, ear suffocation sense, auditory dysesthesia, diplopia and headache etc. in nasal obstruction, tears.The large multipair radiotherapy of nasopharyngeal carcinoma has medium sensitivity, and radiotherapy is the first-selected Therapeutic Method of nasopharyngeal carcinoma.But to compared with well-differentiated carcinoma, the case of the more late and recurrence after radiotherapy of the course of disease, excision and chemotherapy also belong to indispensable means.
A large amount of studies confirm that, tumor is a class cell cycle disease, one of feature of tumor is that cell cycle is abnormal, make tumor cell infinite multiplication, during any one of cell cycle, the biosynthesis of phase is blocked, all can make the seriality of cell cycle interrupt, the key link of oncotherapy is exactly the cell cycle of blocking-up tumor cell, cell death inducing.
Apoptosis betides in all tumor tissues, with generation, the development of tumor and shift closely related.Chemotherapeutics mainly reaches therapeutic effect by cancer cell specific induction of apoptosis, and therefore, inducing apoptosis of tumour cell becomes the focus of research oncotherapy.
Apoptotic feature is that cell volume dwindles, immediately with contiguous cell be connected forfeitures, each other disengaging, lose microvillus, endochylema is concentrated, and reticulum dilatation is blister and merges with cell membrane, mitochondrion is without large variation, and nuclear chromatin is concentrated is semilune, and chromatin agglutination is close to nuclear membrane periphery, kernel cracking, and then cell membrane caves in, and forms apoptotic body, apoptotic process does not cause lysosome to break, do not have cell inclusion to leak, thus do not cause inflammation reaction and secondary damage, Ca
2+/ Mg
2+dependence endonuclease activity increases, and makes DNA degradation, and DNA electrophoresis shows as scalariform, and these change and have become the apoptotic important indicator of judgement at present.But not mean that the activation of Cobra venom endonuclease is necessary in apoptosis process, in some apoptosis, not necessarily occur that DNA electrophoresis is scalariform.
Whether apoptotic generation needs the active of new RNA and protein synthetic, depends on cell type and apoptosis-induced factor, and perhaps some signal pathway needs the expression of new gene, and some does not need.Have report apoptotic cell there is no DNA degradation, prompting DNA degradation is not essential in apoptosis process yet.Apoptosis is a very complicated physiology and pathological process, and the inside and outside many factors of body can affect apoptotic generation, and is obviously subject to molecular genetics impact.Different tumor cells is different to the variable concentrations sensitivity of different pharmaceutical or same medicine, can activate a kind of material of apoptosis of tumor cells effect, may be invalid to another kind of tumor cell.Such as paclitaxel is mainly applicable to ovarian cancer and breast carcinoma, pulmonary carcinoma, colorectal cancer, melanoma, incidence cancer, lymphoma, cerebroma are also had to certain curative effect.The cancer of controlling other is poor effect.In a word, apoptotic molecular mechanism it be unclear that, and awaits further investigation.
Stahlianthus hainanensis (Hayata) T. L. Wu is root stock and the tuber of zingiberaceous plant Folium Zingiberis Radix Notoginseng Stahlianthus involucratus (King ex Bak.) Craib.Tool heat clearing away, dampness removing, pain relieving, removing toxic substances, the effect of hemostasis, for stranguria with turbid discharge, stomachache, aphtha, hemorrhoid, ulcer, traumatic injury, venom, the diseases such as traumatic hemorrhage, are Guangxi Special Traditional Chinese Medicine material.
" China's Zingiberaceae medicinal plants study VI Radix Camptandrae Yunnanensis Analysis of The Essential Oil " (being published in < < chromatograph > > the 1st the 1st phase of volume in 1984), by gas-liquid chromatograph, with gas-liquid chromatograph-mass spectrography, each composition of Radix Camptandrae Yunnanensis volatile oil is shared and identified, identify Dihydrostahlianthusone, australene, camphene, nopinene, carene, limonene, cineole, linalool, Camphora, α-capaene, trans-Flos Caryophylli alkene, aromadendrene, γ-muurolene, cadinene, 15 kinds of compositions such as Stahlianthusone.
Application number is CN200510098945.2 " a kind of medicine for external use of Stahlianthus hainanensis (Hayata) T. L. Wu ", a kind of medicine for external use being comprised of Stahlianthus hainanensis (Hayata) T. L. Wu, Sabia schumanniana Diels, Herba asplenii prolongati, Herba Tetrastigmatis yunnanensis, Cortex Aceris Sinensis, Prunus brachypoda Batal. Var.eglandulosa Cheng, Caulis Trachelospermi, ethanol is disclosed, rheumatic arthritis, traumatic injury stasis of blood pain, traumatic injury, traumatic hemorrhage, arthralgia, muscles and bones are sprained to pain, bones and muscles pain, pain caused by ecchymoma, lumbocrural pain, joint aches, wound stasis of blood pain, soft tissue contusion's determined curative effect, the course for the treatment of is shorter, and effect is better.
In addition Stahlianthus hainanensis (Hayata) T. L. Wu or the therapeutic effect of Rhizoma Stahlianthi Involucrati aspect traumatic injury or rheumatism are all mentioned in the patent application that the patent application that the patent application that, publication number is CN1814229 " a kind of damp-repellent pain-relieving medicinal liquor of Radix Vaccinii Fragilis ", publication number are CN1742972 " a kind of Chloranthus multistachys Pei medicine for external use ", publication number are CN1814230 " a kind of Herba Viciae Amoenae activating collaterals to relieve pain medicine ", the patent application " a kind of radix-Gynurae-Bodinieri collateral-flow-activating pain-relieving ointment for treating affection by dampness " that publication number is CN1814228, the patent application " damp-clearing pain-relieving liquor and acupoint application treatment method " that publication number is CN101766729.
In existing open source literature, or mention the volatile oil component of Stahlianthus hainanensis (Hayata) T. L. Wu, or mention the effect of the diseases such as Stahlianthus hainanensis (Hayata) T. L. Wu treatment traumatic injury, but have no the effect that open use Stahlianthus hainanensis (Hayata) T. L. Wu, Stahlianthus hainanensis (Hayata) T. L. Wu extract, Stahlianthus hainanensis (Hayata) T. L. Wu liposoluble extract and Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil are used for the treatment of tumor, various cancers, not yet there is the open Stahlianthus hainanensis (Hayata) T. L. Wu of people to can be used for treating nasopharyngeal carcinoma, also there is no the impact of the open Stahlianthus hainanensis (Hayata) T. L. Wu of report on cell cycle of human nasopharyngeal carcinoma, propagation or apoptosis.
Summary of the invention
The object of this invention is to provide Stahlianthus hainanensis (Hayata) T. L. Wu plant and in preparation, treat and/or prevent the application of medicine for nasopharyngeal;
The object of this invention is to provide Stahlianthus hainanensis (Hayata) T. L. Wu extract and in preparation, treat and/or prevent the application of medicine for nasopharyngeal;
The object of this invention is to provide Stahlianthus hainanensis (Hayata) T. L. Wu extractive of volatile oil and in preparation, treat and/or prevent the application of medicine for nasopharyngeal;
Another object of the present invention is to provide the preparation method of Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil.
Stahlianthus hainanensis (Hayata) T. L. Wu is root stock, the tuber of zingiberaceous plant Folium Zingiberis Radix Notoginseng Stahlianthus involucratus (King ex Bak.) Craib.After time of the year when autumn changes into winter blade is withered and yellow, excavate, remove impurity, clean, put rapid iron in boiling water, dry.Record in the 8th page of < < Guangxi Chinese crude drug standard > > nineteen ninety version.
The another name of Stahlianthus hainanensis (Hayata) T. L. Wu has Radix Notoginseng Rhizoma Zingiberis Recens, Stahlianthus hainanensis (Hayata) T. L. Wu, Rhizoma Stahlianthi Involucrati, Folium Bambusae Radix Notoginseng, Stahlianthus hainanensis (Hayata) T. L. Wu, Cor Gigeriae Galli seven, red husky Rhizoma Zingiberis Recens, sharp Radix Notoginseng, drags top rifle (Zhuang), internal diabetes, DABUSI etc.
According to inventor, Stahlianthus hainanensis (Hayata) T. L. Wu plant, Stahlianthus hainanensis (Hayata) T. L. Wu extract, Stahlianthus hainanensis (Hayata) T. L. Wu liposoluble extract and Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil are carried out to clinical research and pharmacodynamic study, find that Stahlianthus hainanensis (Hayata) T. L. Wu plant, Stahlianthus hainanensis (Hayata) T. L. Wu extract, Stahlianthus hainanensis (Hayata) T. L. Wu liposoluble extract and Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil can be by suppressing nasopharyngeal carcinoma cell propagation, affecting nasopharyngeal carcinoma cell generation apoptosis, and the change that affects cell cycle of human nasopharyngeal carcinoma, reach anti-nasopharyngeal cancer cell activity, treatment nasopharyngeal carcinoma effect.
On this basis, the inventor is by having object to extract and after content controls to the effective ingredient of Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, it is used for the treatment of and/or the more remarkable effect of prophylaxis of cancer.Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is compared with other Stahlianthus hainanensis (Hayata) T. L. Wu extracts, nasopharyngeal carcinoma cell HEPG2 is had more to significant inhibitory action, the normal conversion that can effectively suppress cell cycle, cell was piled up in the G1 phase, cell block is in the G1 phase, thereby the mitosis that stops cell, is suppressed cell proliferation.
The safety of patent clinical practice of the present invention is higher, a kind of good medicine of can yet be regarded as in the Drug therapy of nasopharyngeal carcinoma, and it has widened the new method of Chinese medicine preparation treatment nasopharyngeal carcinoma, particularly applicable at the basic hospital that can not carry out interventional therapy.
Therefore, applicant provides Stahlianthus hainanensis (Hayata) T. L. Wu plant, Stahlianthus hainanensis (Hayata) T. L. Wu extract, Stahlianthus hainanensis (Hayata) T. L. Wu liposoluble extract, Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil for the preparation of the new purposes that treats and/or prevents medicine for nasopharyngeal aspect.
The invention discloses Stahlianthus hainanensis (Hayata) T. L. Wu extract and in preparation, treat and/or prevent the application of medicine for nasopharyngeal, the preparation of described Stahlianthus hainanensis (Hayata) T. L. Wu extract comprises the following steps: get the chopping of Stahlianthus hainanensis (Hayata) T. L. Wu rhizome, extracting in water decocts twice, the decocting that adds for the first time medical material weight 2-6 doubly to measure boils, and boils 1-3 hour after boiling, and the decocting that adds for the second time medical material weight 1-4 doubly to measure boils 1-3 hour, filter, mix decoction liquor twice, be concentrated into the 0.5-2 of medical material gross weight doubly, obtain.
The invention discloses Stahlianthus hainanensis (Hayata) T. L. Wu extract and in preparation, treat and/or prevent the application of medicine for nasopharyngeal, the preparation of described Stahlianthus hainanensis (Hayata) T. L. Wu extract is further comprising the steps of: get the chopping of Stahlianthus hainanensis (Hayata) T. L. Wu rhizome, add alcohol reflux 2-3 time, add for the first time the ethanol that 2-6 times of percent by volume is 40-70%, extract 1-3 hour, add for the second time 1-4 doubly to measure the ethanol extraction 1-3 hour that percent by volume is 40-70%, collecting decoction, filters, and reclaims ethanol, make dry cream, obtain.
The invention also discloses Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract and in preparation, treat and/or prevent the application of medicine for nasopharyngeal, the preparation of described Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract comprises the following steps: get the chopping of Stahlianthus hainanensis (Hayata) T. L. Wu rhizome, add petroleum ether reflux, extract, 2-3 time, add medical material gross weight 3-5 petroleum ether doubly at every turn, extraction time is 1-3 hour, and merge extractive liquid, filters, reclaim petroleum ether, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
The invention discloses Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract and in preparation, treat and/or prevent the application of medicine for nasopharyngeal, the preparation of described Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract can also comprise the following steps: get the chopping of Stahlianthus hainanensis (Hayata) T. L. Wu rhizome, adding ethyl acetate backflow extracts 2-3 time, add medical material gross weight 3-5 ethyl acetate doubly at every turn, extraction time is 1-3 hour, and merge extractive liquid, filters, reclaim ethyl acetate, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
The invention discloses Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract and in preparation, treat and/or prevent the application of medicine for nasopharyngeal, the preparation of described Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract can also comprise the following steps: get the chopping of Stahlianthus hainanensis (Hayata) T. L. Wu rhizome, add water-saturated n-butanol reflux, extract, 2-3 time, add medical material gross weight 3-5 water-saturated n-butanol doubly at every turn, extraction time is 1-3 hour, and merge extractive liquid, filters, reclaim water-saturated n-butanol, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
The invention discloses Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract and in preparation, treat and/or prevent the application of medicine for nasopharyngeal, the preparation of described Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract can also comprise the following steps: get the chopping of Stahlianthus hainanensis (Hayata) T. L. Wu rhizome, add alcohol reflux 2-3 time, add at every turn medical material gross weight 3-5 doubly, the percent by volume ethanol that is 30-50%, extraction time is 1-3 hour, and merge extractive liquid, filters, reclaim ethanol, obtain concentrated solution.
Described concentrated solution adds petroleum ether and divides 3 extractions, and the 3-5 that each petroleum ether consumption is concentrated solution volume doubly, collects petroleum ether phase, and concentrate drying, obtains Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Described concentrated solution adds ethyl acetate and divides 3 extractions, and the 3-5 that each ethyl acetate consumption is concentrated solution volume doubly, collects petroleum ether phase, and concentrate drying, obtains Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Described concentrated solution adds water-saturated n-butanol and divides 3 extractions, and the 3-5 that each water-saturated n-butanol consumption is concentrated solution volume doubly, collects water-saturated n-butanol phase, and concentrate drying, obtains Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
The invention discloses Stahlianthus hainanensis (Hayata) T. L. Wu volatile-oil composite and in preparation, treat and/or prevent the application of medicine for nasopharyngeal, in described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, contain active ingredient, the Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil active ingredient that this active ingredient is extracted by Stahlianthus hainanensis (Hayata) T. L. Wu forms, comprising monoterpenes compound, the oxide-based compound of monoterpene, sesquiterpenoids, the oxide-based compound of sesquiterpene.
Preferably, described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil active ingredient comprises: 3,6,7 of 20-30 weight portion, 8-tetrahydro-3,3,6,6-tetramethyl cyclopenta [E] indenes-1 (2H)-one, the camphene of 8-20 weight portion; 1,7 of 6-15 weight portion, 7-trimethyl-bicyclo-[2.2.1] heptan-2-thatch ketone, the aromadendrene of 2-8 weight portion; The caryophyllene oxide of 1-6 weight portion.
More preferably, described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil active ingredient content comprises: 3,6,7 of 24-28 weight portion, 8-tetrahydro-3,3,6,6-tetramethyl cyclopenta [E] indenes-1 (2H)-one, the camphene of 11-15 weight portion; 1,7 of 8-12 weight portion, 7-trimethyl-bicyclo-[2.2.1] heptan-2-thatch ketone, the aromadendrene of 3-6 weight portion; The caryophyllene oxide of 2-5 weight portion.
Applicant also provides a kind of method of preparing described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, and it comprises the steps:
Get Stahlianthus hainanensis (Hayata) T. L. Wu and be ground into coarse powder, add medical material gross weight 3-7 distilled water immersion 0.5-3 hour doubly, by water vapour distillation 3-6 hour, collect upper strata quintessence oil, obtain Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil.
Preferably, the preparation of Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil comprises the following steps:
Get Stahlianthus hainanensis (Hayata) T. L. Wu and pulverize, add the distilled water immersion 1h of 5 times of medical material gross weights, by water vapour distillation 4h, collect upper strata quintessence oil and obtain Stahlianthus hainanensis (Hayata) T. L. Wu volatile-oil composite.
Based on above-mentioned Stahlianthus hainanensis (Hayata) T. L. Wu extract, Stahlianthus hainanensis (Hayata) T. L. Wu liposoluble extract, Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, the object of this invention is to provide a kind of new purposes of above compositions, in preparation, treat and/or prevent the application of medicine for nasopharyngeal.It can make injection, powder ampoule agent for injection, and freeze-dried powder injection, tablet, pill, powder, granule, mixture, syrup, capsule, drop pill preparation, preferably make injection, freeze-dried powder injection.The medicine of above-mentioned various dosage forms all can be according to the conventional method preparation of pharmaceutical field.
Below the crude drug source of Chinese medicine preparation of the present invention:
Stahlianthus hainanensis (Hayata) T. L. Wu: root stock and the tuber of zingiberaceous plant Folium Zingiberis Radix Notoginseng Stahlianthus involucratus (King ex Bak.) Craib.
The invention discloses the new purposes of Stahlianthus hainanensis (Hayata) T. L. Wu in treatment nasopharyngeal carcinoma, the former plant of Stahlianthus hainanensis (Hayata) T. L. Wu and common process extract have certain therapeutic effect for treatment nasopharyngeal carcinoma, the visible experimental example 1 of result and experimental example 2, and, Stahlianthus hainanensis (Hayata) T. L. Wu toxicity is little, can not produce the strong side effect such as chemotherapy.
The extractive of volatile oil of Stahlianthus hainanensis (Hayata) T. L. Wu has outstanding curative effect, cell experiment as shown in experimental example, its concentration is when 120 μ g/ml, just there is obvious activity, when concentration is 240 μ g/ml, act on, after 12 hours, the suppression ratio of nasopharyngeal carcinoma cell has been surpassed to control drug group, the volatile oil of Stahlianthus hainanensis (Hayata) T. L. Wu suppresses nasopharyngeal carcinoma cell activity higher than cisplatin group, and its concentration is at 360 μ g/ml when above, its activity of killing nasopharyngeal carcinoma cell can surpass 90% especially.
Accompanying drawing explanation
Fig. 1 is that Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is to human nasopharyngeal epithelioma 1 (CNE-2) proliferation inhibition rate line chart
Fig. 2 is the metamorphosis of Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil to human nasopharyngeal epithelioma 1 CNE-2 apoptosis
Fig. 3 is the impact of Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil on CNE-2 cell cycle
Fig. 4 is that Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is to human nasopharyngeal epithelioma 1 (CNE-2) early apoptosis Annexin V-PI double-staining fluorescence scatterplot
Fig. 5 Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is to human nasopharyngeal epithelioma 1 (CNE-2) apoptosis rate bar diagram
The specific embodiment
Below by embodiment, further illustrate the present invention.It should be understood that embodiments of the invention are for the present invention rather than limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent in the present invention is percetage by weight (ethanol is percent by volume).
Embodiment 1: Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil
Get fresh Stahlianthus hainanensis (Hayata) T. L. Wu 150g and be ground into coarse powder, add the distilled water immersion 0.5h of medical material 450ml, by water vapour distillation 3h, collect upper strata quintessence oil, obtain Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil 1.7ml.
Gained Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is detected to component content result: 3,6,7,8-tetrahydro-3,3,6,6-tetramethyl cyclopenta [E] indenes-1 (2H)-one is 24%, camphene is 15%; 1,7,7-trimethyl-bicyclo-[2.2.1] heptan-2-thatch ketone is 12%, and aromadendrene is 3%; Caryophyllene oxide is 2%.
Embodiment 2: Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil
Get fresh Stahlianthus hainanensis (Hayata) T. L. Wu rhizome 150g and pulverize, add the distilled water immersion 1h of 750ml, by water vapour distillation 4h, collect upper strata quintessence oil, obtain Stahlianthus hainanensis (Hayata) T. L. Wu volatile-oil composite 2.2ml.
Gained Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is detected to component content result: 3,6,7,8-tetrahydro-3,3,6,6-tetramethyl cyclopenta [E] indenes-1 (2H)-one is 28%, camphene is 11%; 1,7,7-trimethyl-bicyclo-[2.2.1] heptan-2-thatch ketone is 8%, and aromadendrene is 6%; Caryophyllene oxide is 5%.
Embodiment 3: Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil
Get Stahlianthus hainanensis (Hayata) T. L. Wu dry rhizome 150g and pulverize, add 1050ml distilled water immersion 3h, by water vapour distillation 6h, collect upper strata quintessence oil, obtain Stahlianthus hainanensis (Hayata) T. L. Wu volatile-oil composite 2.0ml.
Gained Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is detected to component content result: 3,6,7,8-tetrahydro-3,3,6,6-tetramethyl cyclopenta [E] indenes-1 (2H)-one is 30%, camphene is 20%; 1,7,7-trimethyl-bicyclo-[2.2.1] heptan-2-thatch ketone is 15%, and aromadendrene is 2%; Caryophyllene oxide is 1%.
Embodiment 4: Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract
Get Stahlianthus hainanensis (Hayata) T. L. Wu rhizome 5000g chopping, add petroleum ether reflux, extract, 2 times, add for the first time 20000ml petroleum ether, extract 2 hours, add for the second time 15000ml Petroleum ether extraction 2 hours, merge extractive liquid,, filter, reclaim petroleum ether, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Embodiment 5: Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract
Get Stahlianthus hainanensis (Hayata) T. L. Wu rhizome 5000g chopping, add petroleum ether reflux, extract, 3 times, add for the first time 25000ml petroleum ether, extract 3 hours, add for the second time 20000ml Petroleum ether extraction 2 hours, adding for the third time the 15000ml Petroleum ether extraction time is 1 hour, merge extractive liquid,, filter, reclaim petroleum ether, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Embodiment 6: Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract
Get Stahlianthus hainanensis (Hayata) T. L. Wu rhizome 5000g chopping, adding ethyl acetate backflow extracts 3 times, add for the first time 25000ml ethyl acetate, extract 3 hours, add for the second time 20000ml ethyl acetate to extract 2 hours, add for the third time 15000ml ethyl acetate, extraction time is 1 hour, and merge extractive liquid, filters, reclaim ethyl acetate, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Embodiment 7: Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract
Get Stahlianthus hainanensis (Hayata) T. L. Wu rhizome 5000g chopping, add water-saturated n-butanol reflux, extract, 3 times, add for the first time 25000ml water-saturated n-butanol, extract 3 hours, add for the second time 20000ml water-saturated n-butanol to extract 2 hours, adding for the third time 15000ml water-saturated n-butanol to carry extraction time is 1 hour, merge extractive liquid,, filter, reclaim water-saturated n-butanol, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Embodiment 8: Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract
Get Stahlianthus hainanensis (Hayata) T. L. Wu dry rhizome 5000g chopping, add alcohol reflux 2 times, adding for the first time 25000ml percent by volume is 40% ethanol, extract 3 hours, adding for the second time 15000ml percent by volume is 50% ethanol extraction 2 hours, and merge extractive liquid,, filters, reclaim ethanol, concentrated solution adds petroleum ether and divides 3 extractions, and each petroleum ether consumption is respectively 5 times, 4 times, 3 times of concentrated solution volume, collects petroleum ether phase, concentrate drying, obtains Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Embodiment 9: Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract
Get Stahlianthus hainanensis (Hayata) T. L. Wu dry rhizome 5000g chopping, add alcohol reflux 3 times, adding for the first time 20000ml percent by volume is 30% ethanol, extract 3 hours, adding for the second time 15000ml percent by volume is 40% ethanol extraction 2 hours, adding for the third time 10000ml percent by volume is 50% ethanol extraction 1 hour, merge extractive liquid, filter, reclaim ethanol, concentrated solution adds ethyl acetate and divides 3 extractions, each ethyl acetate consumption is respectively 5 times of concentrated solution volume, 4 times, 3 times, collect ethyl acetate phase, concentrate drying, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Embodiment 10: Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract
Get Stahlianthus hainanensis (Hayata) T. L. Wu dry rhizome 5000g chopping, add alcohol reflux 3 times, adding for the first time 20000ml percent by volume is 30% ethanol, extract 3 hours, adding for the second time 15000ml percent by volume is 40% ethanol extraction 2 hours, adding for the third time 10000ml percent by volume is 50% ethanol extraction 1 hour, merge extractive liquid, filter, reclaim ethanol, concentrated solution adds water-saturated n-butanol and divides 3 extractions, each water-saturated n-butanol consumption is respectively 5 times of concentrated solution volume, 4 times, 3 times, collect water-saturated n-butanol phase, concentrate drying, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Embodiment 11: Stahlianthus hainanensis (Hayata) T. L. Wu water extract
Get fresh Stahlianthus hainanensis (Hayata) T. L. Wu rhizome 1000g chopping, add for the first time 6000ml and decoct, after boiling, keep 3h, add for the second time 4000ml water boiling and extraction 1h.Merge decocting liquid twice, filter, be concentrated into 2000ml, obtain Stahlianthus hainanensis (Hayata) T. L. Wu water extract.
Embodiment 12: Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract
Get fresh Stahlianthus hainanensis (Hayata) T. L. Wu rhizome 1000g chopping, add alcohol reflux 2 times, add for the first time the ethanol that 6 times of percents by volume are 70%, extract to add for the second time 4 times of amount percents by volume be 40% ethanol extraction 1 hour, collecting decoction 3 hours, filter, reclaim ethanol, make dry cream, obtain Stahlianthus hainanensis (Hayata) T. L. Wu fat soluble component extract.
Embodiment 13: Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil injection
Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil in embodiment 1-3 and glucose, appropriate cosolvent, appropriate solvent is even, filter, sterilizing, prepares injection.
Embodiment 14: Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil lyophilized injectable powder
Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil in embodiment 1-3 and glucose, appropriate cosolvent, appropriate solvent is even, sterilizing, be sub-packed in the containers such as ampoule or cillin bottle, in sterile closed environment, under low temperature, freeze, then by reducing ambient pressure, the method for the products temperature that slowly raises makes the solvent distillation in goods, leave the medicine of solid forms, obtain freeze-dried powder of the present invention.
Embodiment 15: Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil
Get Stahlianthus hainanensis (Hayata) T. L. Wu dry rhizome 150g and pulverize, add 600ml distilled water immersion 2h, by water vapour distillation 5h, collect upper strata quintessence oil, obtain Stahlianthus hainanensis (Hayata) T. L. Wu volatile-oil composite 1.9ml.
Gained Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is detected to component content result: 3,6,7,8-tetrahydro-3,3,6,6-tetramethyl cyclopenta [E] indenes-1 (2H)-one is 20%, camphene is 8%; 1,7,7-trimethyl-bicyclo-[2.2.1] heptan-2-thatch ketone is 6%, and aromadendrene is 8%; Caryophyllene oxide is 6%.
Effect experiment
Experimental example 1 the present invention is to nasopharyngeal carcinoma cell inhibited proliferation
Get Stahlianthus hainanensis (Hayata) T. L. Wu volatile-oil composite, ligroin extraction, ethyl acetate extract, water-saturated n-butanol extract, water extract and ethanol extraction in embodiment 2,5,6,7,11,12, with RPMI1640 culture fluid, said extracted thing is diluted, 0.22 μ m micropore filter sucking filtration degerming, 4 ℃ save backup.
With mtt assay, detect the present invention to nasopharyngeal carcinoma cell inhibited proliferation.
1 sample and Experimental agents
1.1 nasopharyngeal carcinoma cells are cultivated
RPMI1640 culture medium containing 10% hyclone and 100 μ g/ml penicillin-streptomycins for KB cell (CNE-2), puts 37 ℃, 5%CO
2, cultivate and go down to posterity in the constant-temperature enclosed incubator under saturated humidity condition.0.02EDTA-0.25% trypsinization, every 2～3d goes down to posterity once.
1.2 Experimental agents
Experimental group: embodiment 2,5,6,7,11,12.
Comparative example medicine: cisplatin, Dezhou Deyao Pharmaceutical Co., Ltd of manufacturer; Lot number: the accurate word H37020524 of traditional Chinese medicines; Concentration 3 μ g/ml.
2MTT method detects Stahlianthus hainanensis (Hayata) T. L. Wu extract to nasopharyngeal carcinoma cell inhibited proliferation
Table 1 embodiment of the present invention and the cisplatin suppression ratio to nasopharyngeal carcinoma cell propagation
Experimental result shows: 2 pairs of nasopharyngeal carcinoma cell inhibited proliferations of embodiment are obviously better than other embodiment groups and cisplatin group; Each embodiment group is compared with cisplatin group, has by force a little less than nasopharyngeal carcinoma cell inhibited proliferation is had, but all embody, the propagation of nasopharyngeal carcinoma cell is had to inhibitory action.By obtaining conclusion above:
1, Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is obviously better than to the inhibited proliferation of nasopharyngeal carcinoma cell the extract that Stahlianthus hainanensis (Hayata) T. L. Wu obtains through other extracting method, and is obviously better than cisplatin.。
2, Stahlianthus hainanensis (Hayata) T. L. Wu ligroin extraction, ethyl acetate extract are better than Stahlianthus hainanensis (Hayata) T. L. Wu water-saturated n-butanol extract, Stahlianthus hainanensis (Hayata) T. L. Wu water extract, Stahlianthus hainanensis (Hayata) T. L. Wu ethanol extraction and cisplatin to the inhibited proliferation of nasopharyngeal carcinoma cell.
3, Stahlianthus hainanensis (Hayata) T. L. Wu water extract, ethanol extraction and water-saturated n-butanol extract are compared poorly with cisplatin group to the inhibited proliferation of nasopharyngeal carcinoma cell, but can demonstrate equally, nasopharyngeal carcinoma cell propagation are had to inhibitory action.
Experimental example 2 Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil In Vitro Anti nasopharyngeal carcinoma cell activity experiments
1 instrument and reagent
1.1 instrument
Volatile oil determination apparatus meets the related standards of an appendix XD determination of volatile oil method of Chinese Pharmacopoeia; Galaxy170S type CO2 cell culture incubator (German Eppendorf company), MLDEL680 type microplate reader (Japanese BIO-RAD company), Axiovert-40 type inverted phase contrast microscope (Zeiss, Germany company), SW-CJ-2F type superclean bench (Purifying Equipment Co., Ltd., Suzhou).
1.2 reagent
Hyclone, RPMI1640 culture medium are all purchased from U.S. hyclone company; DMSO, tetramethyl azo azoles blue (MTT) are all purchased from Sigma company; Other reagent such as ether are domestic analytical pure.
1.3 Experimental agents
Experimental group: embodiment 1, Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil.
Comparative example medicine: cisplatin, Dezhou Deyao Pharmaceutical Co., Ltd of manufacturer; Lot number: the accurate word H37020524 of traditional Chinese medicines; Concentration 3 μ g/ml.
1.4 for examination nasopharyngeal carcinoma cell
KB cell (CNE-2) is provided by Medical Colleges Of Guilin's scientific experiments center.
2 methods and result
2.1 method
2.1.1 medicine preparation
With RPMI1640 culture fluid, the extractive of volatile oil of embodiment 1 gained (20mg/mL) is diluted in 1:10,1:13,1:20,1:40 ratio, 0.22 μ m micropore filter sucking filtration degerming, 4 ℃ save backup.
2.1.2 experiment grouping:
A: blank group
B:120 μ g/ml Stahlianthus hainanensis (Hayata) T. L. Wu volatilization line of oils
C:240 μ g/ml Stahlianthus hainanensis (Hayata) T. L. Wu volatilization line of oils
D:360 μ g/ml Stahlianthus hainanensis (Hayata) T. L. Wu volatilization line of oils
E:480 μ g/ml Stahlianthus hainanensis (Hayata) T. L. Wu volatilization line of oils
2.1.3 nasopharyngeal carcinoma cell is cultivated
RPMI1640 culture medium containing 10% hyclone and 100 μ g/ml penicillin-streptomycins for KB cell (CNE-2), puts 37 ℃, 5%CO
2, cultivate and go down to posterity in the constant-temperature enclosed incubator under saturated humidity condition.0.02EDTA-0.25% trypsinization, every 2～3d goes down to posterity once.
2.1.4MTT method detects medicine of the present invention to nasopharyngeal carcinoma cell inhibited proliferation
The nasopharyngeal carcinoma cell of exponential phase is inoculated to 96 well culture plates, 37 ℃, 5%CO by 4000, every hole
2in incubator, cultivate 12h, 24h, 36h, 48h, 60h, after cell attachment, adds respectively cell strain to grow up in 96 porocyte culture plates of monolayer variable concentrations Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, each concentration repeats 5 multiple holes, set up two matched groups: one is blank group (not adding cell), one is cell matched group (add RPMI-1640, the concentration of Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is 0) simultaneously.Be placed in 37 ℃, 5%CO
2in incubator, cultivate 24h.Cultivation finishes front 4h, inhales and abandons liquid in culture plate, and PBS rinses 3 times, and under lucifuge condition, every hole adds MTT (5mg/ml) 20 μ l, is placed in 37 ℃, 5%CO
2in incubator, continue to cultivate 4h, remove supernatant after every hole add DMSO150 μ l, horizontal shaking table concussion 10min, elisa reading instrument colorimetric (wavelength 490nm) is surveyed absorbance.Experiment repeats 3 times.Experiment with computing medicine and the control drug inhibitory action to nasopharyngeal carcinoma cell (CNE-2) as follows.Cell inhibitory rate (%)=(1-drug effect group absorbance/cell matched group absorbance) * 100%.
2.1.5Hoechst33258 dyeing observation of cell form
Get the clean coverslip being soaked in 70% ethanol, be placed in six orifice plates, A group (blank group) is set, B group (120 μ g/ml) C group (240 μ g/ml), D group (360 μ g/ml), with aseptic PBS tri-times, then wash one time with cell culture fluid in aseptic super-clean bench.The different nasopharyngeal carcinoma cells (CNE-2) of the trophophase of taking the logarithm, every hole inoculation 5x10
4individual cell culture spends the night.After variable concentrations Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is processed 24h, exhaust culture fluid, PBS washing 3 times, adds 0.5ml fixative, fixes 30 minutes.Remove fixative, with PBS, wash 2 times, each 3 minutes, exhaust liquid.Add 0.5ml Hoechst33258 dyeing liquor, dye 10 minutes.Remove dyeing liquor, with PBS, wash 2 times, each 3 minutes, exhaust liquid.Drip anti-fluorescent quenching mounting liquid on microscope slide, cover the coverslip that posts cell, allow cells contacting mounting liquid, avoid bubble as far as possible.With about fluorescence exciting wavelength 350nm, emission wavelength 460nm left and right can detect the nucleus that is blue under fluorescence microscope.
2.1.6 flow cytometer detects volatile oil to cell cycle of human nasopharyngeal carcinoma and apoptotic impact
KB cell (CNE-2) is divided into four groups: A group (blank group), B group (120 μ g/ml), C group (240 μ g/ml), D group (360 μ g/ml), after treatment, after collecting all cells (adherent and suspension cell), with PBS, clean once, every group adds respectively 100 μ l buffer, piping and druming evenly, add respectively again 3 μ l PI and 3 μ Annexin-V, lucifuge dyeing 1 hour, add 200 μ l buffer, 200 mesh filter screen filtration cells, are collected in flow cytometer loading pipe.Use 488nm laser as excitation wavelength, 525nm is as detecting wavelength, on flow cytometer to 10,000 cell collection fluorescence intensity data in each sample.
2.1.7 flow cytometer detects the cycle of nasopharyngeal carcinoma cell
The different nasopharyngeal carcinoma cells of trophophase (CNE-2) of taking the logarithm are divided into A group (blank group), B group (120 μ g/ml) C group (240 μ g/ml), D group (360 μ g/ml) is after different disposal, collect all cells (adherent and suspension cell) in 15ml centrifuge tube after, with PBS, clean once, every group adds respectively 1mL pre-cooling PBS resuspended, and piping and druming evenly.Centrifuge tube is positioned on vortex oscillator, and concussion limit, limit adds the freezing ethanol of 9ml70% to fix, and places-20 ℃ and spends the night.Before dyeing, with pre-cooling PBS, wash, centrifugal (2000r/min, 4 ℃) 5min, removes fixative, with 500 μ L RNaseA digestion, 37 ℃ of water-bath 30min, add again 25 μ L propidium iodide (propdium iodide, PI) dyeing liquors to mix, room temperature lucifuge dyeing 30min, 200 mesh filter screen filtration cells, are collected in flow cytometer loading pipe.Flow cytometer carries out DNA content and cell cycle analysis, draws the percentage rate in each phase of the cycles of cell.
2.1.8 statistical analysis
All experimental datas are with mean ± standard deviation
represent, use SPSS17.0 typing and analytical data, between many groups, data relatively adopts one factor analysis of variance (One-Way ANOVA) check, and P<0.05 represents that difference has significance.
2.2 result
2.2.1 the present invention is to Growth of Nasopharyngeal Carcinoma inhibitory action
Adopt the impact of MTT experimental analysis Experimental agents on KB cell (CNE-2) propagation, result is as shown in table 2 and Fig. 1:
Table 2: different time human nasopharyngeal carcinoma cell line (CNE-2) proliferation inhibition rate
Note:
◇: embodiment group and cisplatin group (positive controls) compare, P value >0.05, embodiment group and cisplatin group relatively do not have significant difference, illustrate that the anti-nasopharyngeal cancer cell activity of embodiment group is equal to cisplatin group substantially.
*: embodiment group and cisplatin group (positive controls) are relatively, P value <0.05, be that embodiment group and cisplatin group relatively have significant difference, from its suppression ratio, analyzed, embodiment group higher than cisplatin group, illustrates that the anti-nasopharyngeal cancer cell activity of embodiment group will be higher than cisplatin group to the suppression ratio of nasopharyngeal carcinoma cell.
△: embodiment group and cisplatin group (positive controls) are relatively, P value <0.01, it is the significant difference that embodiment group and cisplatin group relatively have significance, from its suppression ratio, analyzed, embodiment group is lower than cisplatin group suppression ratio, illustrates that the anti-nasopharyngeal cancer cell activity of embodiment group will or not have anti-nasopharyngeal cancer cell activity lower than cisplatin group.
His-and-hers watches 2 experimental datas are carried out after statistical analysis known, after effect 24 hours, and the IC of volatile oil of the present invention to KB cell (CNE-2)
50be 300 μ g/ml.
Experimental result shows: volatile oil of the present invention has significant inhibitory action to human nasopharyngeal carcinoma cell line (CNE-2), and its successful is better than control drug cisplatin group.And with the prolongation of action time and the increase of drug level, its inhibitory action strengthens gradually, show obvious amount-effect and time-effect relationship.
2.2.2Hoechst33258 dyeing observation of cell form
Hoehst33258 staining observation of cell nuclear morphology changes, and as shown in Figure 2, A group karyomorphism is complete for result, and nuclear membrane is smooth, and chromatin is even, the metamorphosis of the visible division cells core of part; B group, C group, D group be visible nuclear metamorphosis of apoptosis phase all, and nuclear membrane disappears, and core edge is burr shape, nuclear staining is deepened, and part karyopyknosis, is fragmented into the fragment that nuclear membrane is wrapped in, and is graininess, form apoptotic body, occur obvious apoptosis form (as shown by arrows).After the inoculation of equivalent amount cell, with the increase of drug dose, the cell number of various dose concentration experimental group also obviously reduces, and side light Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil increases and strengthens gradually with dosage the effect of human nasopharyngeal epithelioma 1 apoptosis.
2.2.3 flow cytometer detects the impact of Stahlianthus hainanensis (Hayata) T. L. Wu volatile-oil composite on different cell cycle of human nasopharyngeal carcinoma
Flow cytometry (FCM) result shows as Fig. 3 and table 3: after different quality concentration Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil effect KB cell (CNE-2) 24h, compare the variation of B, C, D group (low middle dosage group) cell quantity with A group (blank group):
Fig. 3 and table 3 explanation, at CNE-2, in B, C group, G0/G1 phase cell quantity increases, S phase, G2/M phase cell proportion reduce, and D group (360 μ g/ml experimental group) G1 phase cell proportion reduces, may be, due to Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, CNE-2 is arrested in to the G1 phase, cause apoptosis in nasopharyngeal carcinoma cells, and then causing G1 phase cell proportion to reduce, prompting Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil has obvious G1 phase retardation to CNE-2 cell.
Table 3: Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil is on the impact of CNE-2 cell cycle (%)
2.2.4 flow cytometer detects the apoptosis of nasopharyngeal carcinoma cell
Through flow cytometer, detect the effect of Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil after 24 hours, the apoptosis rate of KB cell (CNE-2) as shown in Figure 4, Figure 5, can be observed the increase with Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil concentration, the ratio that apoptosis occurs KB cell (CNE-2) increases gradually.
In on the impact of CNE-2 apoptosis, B group causes that apoptosis rate is 6%, compares P=0.085>0.05 with blank, and no significant difference, does not have statistical significance.C group and D organize apoptosis rate and sharply rise, and do not present obvious early apoptosis, directly cause cell in, late period apoptosis or necrocytosis, C group, D group have been compared notable difference with blank group.
Experimental result shows: to CNE-2 tumor cell, Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil low dosage has no significant effect effect, and middle high dose group has remarkable effect.Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil has obvious G1 phase retardation to CNE-2 cell, stops the mitosis of cell, cell proliferation is suppressed, thereby reaches anti-nasopharyngeal cancer cell active function.
Claims (9)
1. Stahlianthus hainanensis (Hayata) T. L. Wu plant treats and/or prevents the application of medicine for nasopharyngeal in preparation.
2. Stahlianthus hainanensis (Hayata) T. L. Wu extract treats and/or prevents the application of medicine for nasopharyngeal in preparation.
3. application according to claim 2, is characterized in that: described Stahlianthus hainanensis (Hayata) T. L. Wu extract is the liposoluble constituent in Stahlianthus hainanensis (Hayata) T. L. Wu plant.
4. application as claimed in claim 2, is characterized in that: described Stahlianthus hainanensis (Hayata) T. L. Wu extract is Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil.
5. application as claimed in claim 4, it is characterized in that: in described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, contain active ingredient, the Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil active ingredient that this active ingredient is extracted by Stahlianthus hainanensis (Hayata) T. L. Wu forms, comprising monoterpenes compound, the oxide-based compound of monoterpene, sesquiterpenoids, the oxide-based compound of sesquiterpene.
6. application as claimed in claim 4, is characterized in that: in described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, contain active ingredient, the Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil active ingredient that this active ingredient is extracted by Stahlianthus hainanensis (Hayata) T. L. Wu forms, comprising the composition of following weight proportion:
3,6,7 of 20-30 weight portion, 8-tetrahydro-3,3,6,6-tetramethyl cyclopenta [E] indenes-1 (2H)-one, the camphene of 8-20 weight portion; 1,7 of 6-15 weight portion, 7-trimethyl-bicyclo-[2.2.1] heptan-2-thatch ketone, the aromadendrene of 2-8 weight portion; The caryophyllene oxide of 1-6 weight portion.
7. application as claimed in claim 4, is characterized in that: in described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil, contain active ingredient, the Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil active ingredient that this active ingredient is extracted by Stahlianthus hainanensis (Hayata) T. L. Wu forms, comprising the composition of following weight proportion:
3,6,7 of 24-28 weight portion, 8-tetrahydro-3,3,6,6-tetramethyl cyclopenta [E] indenes-1 (2H)-one, the camphene of 11-15 weight portion; 1,7 of 8-12 weight portion, 7-trimethyl-bicyclo-[2.2.1] heptan-2-thatch ketone, the aromadendrene of 3-6 weight portion; The caryophyllene oxide of 2-5 weight portion.
8. application as claimed in claim 4, is characterized in that, the preparation of described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil comprises the following steps:
Get Stahlianthus hainanensis (Hayata) T. L. Wu and be ground into coarse powder, add medical material gross weight 3-7 distilled water immersion 0.5-3 hour doubly, by water vapour distillation 3-6 hour, collect upper strata quintessence oil, obtain.
9. application as claimed in claim 4, is characterized in that, the preparation of described Stahlianthus hainanensis (Hayata) T. L. Wu volatile oil comprises the following steps:
Get Stahlianthus hainanensis (Hayata) T. L. Wu and be ground into coarse powder, add the distilled water immersion 1h of 5 times of medical material gross weights, by water vapour distillation 4h, collect upper strata quintessence oil, obtain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410173967.XA CN104083689B (en) | 2013-07-17 | 2014-04-28 | Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing nasopharyngeal carcinoma |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310299390.2 | 2013-07-17 | ||
| CN2013102993902 | 2013-07-17 | ||
| CN2013102993902A CN103417889A (en) | 2013-07-17 | 2013-07-17 | Application of stahlianthus involucratus and extractive of stahlianthus involucratus in preparing drugs for treating and/or preventing nasopharynx cancer |
| CN201410173967.XA CN104083689B (en) | 2013-07-17 | 2014-04-28 | Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing nasopharyngeal carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104083689A true CN104083689A (en) | 2014-10-08 |
| CN104083689B CN104083689B (en) | 2017-05-10 |
Family
ID=49643629
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102993902A Pending CN103417889A (en) | 2013-07-17 | 2013-07-17 | Application of stahlianthus involucratus and extractive of stahlianthus involucratus in preparing drugs for treating and/or preventing nasopharynx cancer |
| CN201410173967.XA Expired - Fee Related CN104083689B (en) | 2013-07-17 | 2014-04-28 | Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing nasopharyngeal carcinoma |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013102993902A Pending CN103417889A (en) | 2013-07-17 | 2013-07-17 | Application of stahlianthus involucratus and extractive of stahlianthus involucratus in preparing drugs for treating and/or preventing nasopharynx cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN103417889A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101297940A (en) * | 2008-01-11 | 2008-11-05 | 黄明华 | Medicament for treating tumor and cancer and preparation method |
-
2013
- 2013-07-17 CN CN2013102993902A patent/CN103417889A/en active Pending
-
2014
- 2014-04-28 CN CN201410173967.XA patent/CN104083689B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101297940A (en) * | 2008-01-11 | 2008-11-05 | 黄明华 | Medicament for treating tumor and cancer and preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 倪玲等: "广西壮药姜三七对雌\孕激素负荷大鼠子宫肌瘤的影响", 《时珍国医国药》 * |
| 方洪钜等: "我国姜科药用植物研究Ⅵ姜三七挥发油化学成分分析", 《色谱》 * |
| 李丽淑: "主要栽培技术对"姜三七"产量与药效成分的影响", 《北方园艺》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104083689B (en) | 2017-05-10 |
| CN103417889A (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dutta et al. | Pharmacological evidence for the use of Cissus assamica as a medicinal plant in the management of pain and pyrexia | |
| Yao et al. | Boschniakia rossica polysaccharide triggers laryngeal carcinoma cell apoptosis by regulating expression of Bcl-2, Caspase-3, and P53 | |
| WO2006099804A1 (en) | Herbal compositions useful in cancer treatment | |
| CN101862351B (en) | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine | |
| Saleem et al. | Asphodelus tenuifolius extracts arrested inflammation and arthritis through modulation of TNF-α, NF-κB, ILs, and COX-2 activities in in vivo models | |
| Yue et al. | Efficacy and mechanism of active fractions in fruit of Amomum villosum Lour. for gastric cancer | |
| Xie et al. | Effects of triterpenoid glycosides from fresh ginseng berry on SW480 human colorectal cancer cell line | |
| Kaur et al. | Butea monosperma (Lam.) Taub. Bark fractions protect against free radicals and induce apoptosis in MCF-7 breast cancer cells via cell-cycle arrest and ROS-mediated pathway | |
| Banjare et al. | Boerhaavia diffusa from traditional use to scientific assessment-a review | |
| CN103417679B (en) | Method for extracting anti-cerebral-ischemia material from roses and application of anti-cerebral ischemia material | |
| Yang et al. | Integrating network pharmacology and experimental models to investigate the efficacy of QYHJ on pancreatic cancer | |
| Joseph et al. | Comparative effects of methanol and oil extracts of Ocimum gratissimum on testicular morphology and epididymal sperm reserve of adult male albino rats (Wistar strain) | |
| Chiu et al. | Chinese herbal medicine therapy reduces the risks of overall and anemia-related mortalities in patients with aplastic anemia: A nationwide retrospective study in taiwan | |
| CN101816653A (en) | Application of berberine in preparing tumor radio sensitization medicine | |
| CN101978987A (en) | Application of herba rabdosiae rubescentis extract to preparation of medicament for treating and resisting cerebral ischemia | |
| CN106668041A (en) | Application of rhizoma paridis saponin VI to preparation of anti-lung cancer drugs | |
| CN102670977B (en) | Chinese medicinal composition for treating arthralgia, preparation method and applications of Chinese medicinal composition | |
| CN104096150B (en) | Stahlianthus hainanensis (Hayata) T. L. Wu and its extract are preparing treatment and/or the application of prevention cancer drug | |
| CN104083690B (en) | Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing breast cancer | |
| CN104083689B (en) | Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing nasopharyngeal carcinoma | |
| CN104083688B (en) | Application of Stahlianthus involucratus (King) Craib and its extract in preparation of drugs for treating and/or preventing liver cancer | |
| CN106668042A (en) | Application of Chonglou saponin VII to preparation of anti-lung-cancer medicament | |
| Moeini et al. | The effect of the combination of Malva sylvestris L. and Althaea digitata Boiss. on prevention of acute radiation proctitis in patients with prostate cancer | |
| Hafuth et al. | Investigating the anti-cancer properties of 6-shogaol in Zingiber officinale | |
| Imtiaz et al. | Traditional and contemporary herbal medicines in management of cancer: A scoping review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20191119 Address after: 528448 Zhongshan, torch City, Guangdong, Hong Kong City, Kate residence 18, 1102 rooms. Co-patentee after: Wang Yayan Patentee after: Yang Jianbo Address before: 541004 No. two, 109 North Road, Guilin, the Guangxi Zhuang Autonomous Region Patentee before: GUILIN MEDICAL University |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170510 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |